Clinical Trial: Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07357051) titled 'Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza' on Jan. 08.

Brief Summary: The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

Study Start Date: Nov. 07, 2025

Study Type: INTERVENTIONAL

Condition: Respiratory Viral Infection

Intervention: DRUG: JKN2301 Dry Suspension

Single oral dose, administered according to a weight-tiered dosing scheme.

DRUG: Oseltamivir Placebo

Oral suspension, administered twice da...